Billel Gasmi
Overview
Explore the profile of Billel Gasmi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
6186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leko V, Groh E, Levi S, Copeland A, White B, Gasmi B, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39800378
Background: The use of tumor-infiltrating T lymphocytes (TIL) that recognize cancer neoantigens has led to lasting remissions in metastatic melanoma and certain cases of metastatic epithelial cancer. For the treatment...
2.
Alfaifi A, Wang T, Perez P, Sultan A, Meiller T, Rock P, et al.
PLoS Pathog
. 2024 Dec;
20(12):e1012375.
PMID: 39666753
Saliva contains antimicrobial peptides considered integral components of host innate immunity, and crucial for protection against colonizing microbial species. Most notable is histatin-5 which is exclusively produced in salivary glands...
3.
Robinson W, Stone J, Schischlik F, Gasmi B, Kelly M, Seibert C, et al.
Sci Adv
. 2024 Jul;
10(27):eadj7402.
PMID: 38959321
The study of the tumor microbiome has been garnering increased attention. We developed a computational pipeline (CSI-Microbes) for identifying microbial reads from single-cell RNA sequencing (scRNA-seq) data and for analyzing...
4.
Levin N, Kim S, Marquardt C, Vale N, Yu Z, Sindiri S, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38816232
Background: Tumor-infiltrating lymphocytes (TILs) targeting neoantigens can effectively treat a selected set of metastatic solid cancers. However, harnessing TILs for cancer treatments remains challenging because neoantigen-reactive T cells are often...
5.
Alfaifi A, Wang T, Perez P, Sultan A, Meiller T, Rock P, et al.
bioRxiv
. 2024 May;
PMID: 38798323
Saliva contains antimicrobial peptides considered integral components of host innate immunity, and crucial for protection against colonizing microbial species. Most notable is histatin-5 which is exclusively produced in salivary glands...
6.
Green B, Gamble L, Diggs L, Nousome D, Patterson J, Joughin B, et al.
Mol Cancer Res
. 2023 Sep;
21(12):1356-1365.
PMID: 37707375
Implications: Characterization of the tumor-immune microenvironment in HDGC underscores the potential for the immune system to shape the transcriptional profile of the earliest tumors, which suggests immune-directed therapy as a...
7.
Parikh A, Masi R, Gasmi B, Hanada K, Parkhurst M, Gartner J, et al.
Cancer Immunol Immunother
. 2023 Jun;
72(10):3149-3162.
PMID: 37368077
Adoptive cell transfer of tumor-infiltrating lymphocytes (TIL) can mediate durable complete responses in some patients with common epithelial cancers but does so infrequently. A better understanding of T-cell responses to...
8.
White B, Sindiri S, Hill V, Gasmi B, Nah S, Gartner J, et al.
J Immunother Cancer
. 2023 Apr;
11(4).
PMID: 37045473
Background: Metastatic cholangiocarcinoma (CC), a form of gastrointestinal cancer that originates from the bile ducts, cannot be cured by currently available therapies, and is associated with dismal prognosis. In a...
9.
Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schroder D, Chow A, et al.
Cell
. 2023 Mar;
186(7):1432-1447.e17.
PMID: 37001503
Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple branches of the immune system may eliminate escape variants....
10.
Kim S, Vale N, Zacharakis N, Krishna S, Yu Z, Gasmi B, et al.
Cancer Immunol Res
. 2022 Jun;
10(8):932-946.
PMID: 35749374
Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most neoantigens arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of...